JNJ 10-Q Quarterly Report Sept. 28, 2025 | Alphaminr
Screener Snapshot View

JNJ 10-Q Quarter
ended Sept. 28, 2025


Finance Dashboard
JOHNSON & JOHNSON - JNJ
$201.93
-0.55 (-0.27%)
Market Cap
$486,508,959,947
Enterprise Value
$474,333,959,947
Average Volume
$8,731,022

Valuation & Solvency

P/Tangible Book
6.19
P/E
19.52
P/S
5.28
EV/EBITDA
11.99
EV/Sales
5.15
EV/FCF
24.88
Dividend Yield
2.55%
Payout Ratio
48.70%
Total Debt
$6,387,000,000
Cash & Marketable Securities
$18,562,000,000
Quick Ratio
0.80
Debt/Equity
0.08
Net Debt/EBITDA
-
Interest Coverage Ratio
36.05

About

Industry
Drug Manufacturers - General
Exchange
NYSE
Country
US
Beta
0.35

Company Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.